Parkin loss of function contributes to RTP801 elevation and neurodegeneration in Parkinson's disease

Cell Death and Disease

Volumn 5, Issue 8, 2014, Pages

  Romani Aumedes J ^a   Canal, M ^a   Martin Flores N ^a   Sun, X ^b   Perez Fernandez V ^a   Wewering, S ^c   Fernandez Santiago R ^a,d   Ezquerra, M ^a,d   Pont Sunyer, C ^a   Lafuente, A ^a,d   Alberch, J ^a,d   Luebbert, H ^c   Tolosa, E ^a,d   Levy, O A ^e   Greene, L A ^b   Malagelada, C ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Department of Medicine   (United States)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^e IDIBAPS Institut d'Investigacions Biomèdiques August Pi I Sunyer Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYL-LEUCYL-LEUCINE ALDEHYDE; LEUPEPTIN; OXIDOPAMINE; PARKIN; PROTEASOME; PROTEIN BINDING; REPRESSOR PROTEIN; RTP801 PROTEIN, RAT; SMALL INTERFERING RNA; UBIQUITIN PROTEIN LIGASE;

ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BRAIN; CHEMISTRY; DRUG EFFECTS; GENETICS; HEK293 CELL LINE; HUMAN; KNOCKOUT MOUSE; METABOLISM; MOUSE; NERVE CELL; PARKINSON DISEASE; PATHOLOGY; PC12 CELL LINE; PROTEIN DEGRADATION; RAT; UBIQUITINATION;

ANIMALS; APOPTOSIS; BRAIN; HEK293 CELLS; HUMANS; LEUPEPTINS; MICE; MICE, KNOCKOUT; NEURONS; OXIDOPAMINE; PARKINSON DISEASE; PC12 CELLS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; PROTEOLYSIS; RATS; REPRESSOR PROTEINS; RNA, SMALL INTERFERING; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 84906874980     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.333     Document Type: Article

References (53)

1. Fahn S. Medical treatment of Parkinson's disease. J Neurol 1998; 245(11 Suppl 3): P15-P24.
2. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003; 39: 889-909.
3. Marras C, Lang A. Invited article: changing concepts in Parkinson disease: moving beyond the decade of the brain. Neurology 2008; 70: 1996-2003.
4. Levy OA, Malagelada C, Greene LA. Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps. Apoptosis 2009; 14: 478-500.
5. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 392: 605-608.
6. Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 2000; 25: 302-305.
7. Chung KK, Thomas B, Li X, Pletnikova O, Troncoso JC, Marsh L et al. S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science 2004; 304: 1328-1331.
8. Winklhofer KF, Henn IH, Kay-Jackson PC, Heller U, Tatzelt J. Inactivation of parkin by oxidative stress and C-terminal truncations: a protective role of molecular chaperones. J Biol Chem 2003; 278: 47199-47208.
9. LaVoie MJ, Ostaszewski BL, Weihofen A, Schlossmacher MG, Selkoe DJ. Dopamine covalently modifies and functionally inactivates parkin. Nat Med 2005; 11: 1214-1221.
10. Klein C, Lohmann-Hedrich K, Rogaeva E, Schlossmacher MG, Lang AE. Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol 2007; 6: 652-662.
11. Petrucelli L, O'Farrell C, Lockhart PJ, Baptista M, Kehoe K, Vink L et al. Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 2002; 36: 1007-1019.
12. Staropoli JF, McDermott C, Martinat C, Schulman B, Demireva E, Abeliovich A. Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. Neuron 2003; 37: 735-749.
13. Manfredsson FP, Burger C, Sullivan LF, Muzyczka N, Lewin AS, Mandel RJ. rAAV-mediated nigral human parkin over-expression partially amelioratesmotor deficits via enhanced dopamine neurotransmission in a rat model of Parkinson's disease. Exp Neurol 2007; 207: 289-301.
14. Vercammen L, Van der Perren A, Vaudano E, Gijsbers R, Debyser Z, Van den Haute C et al. Parkin protects against neurotoxicity in the 6-hydroxydopamine rat model for Parkinson's disease. Mol Ther 2006; 14: 716-723.
15. Tain LS, Mortiboys H, Tao RN, Ziviani E, Bandmann O, Whitworth AJ. Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss. Nat Neurosci 2009; 12: 1129-1135.
16. Ellisen LW, Ramsayer KD, Johannessen CM, Yang A, Beppu H, Minda K et al. REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species. Mol Cell 2002; 10: 995-1005.
17. Shoshani T, Faerman A, Mett I, Zelin E, Tenne T, Gorodin S et al. Identification of a novel hypoxia-inducible factor 1-responsive gene, RTP801, involved in apoptosis. Mol Cell Biol 2002; 22: 2283-2293.
18. Ryu EJ, Angelastro JM, Greene LA. Analysis of gene expression changes in a cellular model of Parkinson disease. Neurobiol Dis 2005; 18: 54-74.
19. Malagelada C, Ryu EJ, Biswas SC, Jackson-Lewis V, Greene LA. RTP801 is elevated in Parkinson brain substantia nigral neurons and mediates death in cellular models of Parkinson's disease by a mechanism involving mammalian target of rapamycin inactivation. J Neurosci 2006; 26: 9996-10005.
20. Malagelada C, Jin ZH, Greene LA. RTP801 is induced in Parkinson's disease and mediates neuron death by inhibiting Akt phosphorylation/activation. J Neurosci 2008; 28: 14363-14371.
21. Katiyar S, Liu E, Knutzen CA, Lang ES, Lombardo CR, Sankar S et al. REDD1, an inhibitor of mTOR signalling, is regulated by the CUL4A-DDB1 ubiquitin ligase. EMBO Rep 2009; 10: 866-872.
22. Kimball SR, Do AN, Kutzler L, Cavener DR, Jefferson LS. Rapid turnover of the mTOR complex 1 (mTORC1) repressor REDD1 and activation of mTORC1 signaling following inhibition of protein synthesis. J Biol Chem 2008; 283: 3465-3475.
23. Malagelada C, Jin ZH, Jackson-Lewis V, Przedborski S, Greene LA. Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease. J Neurosci 2010; 30: 1166-1175.
24. Malagelada C, Greene L.A. PC12 cells as a model for Parkinson's disease research. In: Przedborski S, Nass R (eds) Parkinson's Disease: Molecular and Therapeutic Insights from Experimental Models. Elsevier, 2008, pp 375-389.
25. Imai Y, Soda M, Takahashi R. Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J Biol Chem 2000; 275: 35661-35664.
26. da Costa CA, Sunyach C, Giaime E, West A, Corti O, Brice A et al. Transcriptional repression of p53 by parkin and impairment by mutations associated with autosomal recessive juvenile Parkinson's disease. Nat Cell Biol 2009; 11: 1370-1375.
27. Unschuld PG, Dachsel J, Darios F, Kohlmann A, Casademunt E, Lehmann-Horn K et al. Parkin modulates gene expression in control and ceramide-treated PC12 cells. Mol Biol Rep 2006; 33: 13-32.
28. Stichel CC, Zhu XR, Bader V, Linnartz B, Schmidt S, Lubbert H. Mono- and double-mutant mouse models of Parkinson's disease display severe mitochondrial damage. Hum Mol Genet 2007; 16: 2377-2393.
29. Harvey BK, Wang Y, Hoffer BJ. Transgenic rodent models of Parkinson's disease. Acta Neurochirurgica Supplement 2008; 101: 89-92.
30. Periquet M, Corti O, Jacquier S, Brice A. Proteomic analysis of parkin knockout mice: alterations in energy metabolism, protein handling and synaptic function. J Neurochem 2005; 95: 1259-1276.
31. Wang Z, Malone MH, Thomenius MJ, Zhong F, Xu F, Distelhorst CW. Dexamethasoneinduced gene 2 (dig2) is a novel pro-survival stress gene induced rapidly by diverse apoptotic signals. J Biol Chem 2003; 278: 27053-27058.
32. Wu T, Hallett M. The cerebellum in Parkinson's disease. Brain 2013; 136(Pt 3): 696-709.
33. Sun X, Liu J, Crary J.F, Malagelada C, Sulzer D, Greene L.A, Levy O.A. ATF4 protects against neuronal death in cellular PD models by maintaining levels of parkin. J Neurosci 2013; 33: 2398-2407.
34. McNaught KS, Belizaire R, Isacson O, Jenner P, Olanow CW. Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol 2003; 179: 38-46.
35. Ebrahimi-Fakhari D, McLean PJ, Unni VK. Alpha-synuclein's degradation in vivo: opening a new (cranial) window on the roles of degradation pathways in Parkinson disease. Autophagy 2012; 8: 281-283.
36. Zhao Y, Xiong X, Jia L, Sun Y. Targeting Cullin-RING ligases by MLN4924 induces autophagy via modulating the HIF1-REDD1-TSC1-mTORC1-DEPTOR axis. Cell Death Dis 2012; 3: e386.
37. Dawson TM, Dawson VL. The role of parkin in familial and sporadic Parkinson's disease. Mov Disord 2010; 25(Suppl 1): S32-S39.
38. Sandebring A, Cedazo-Mínguez A. Parkin - An E3 Ubiquitin Ligase with Multiple Substrates. J Alzheimers Dis Parkinsonism 2012; 2: S10.
39. Zhu XR, Maskri L, Herold C, Bader V, Stichel CC, Gunturkun O et al. Non-motor behavioural impairments in parkin-deficient mice. Eur J Neurosci 2007; 26: 1902-1911.
40. Kitada T, Pisani A, Karouani M, Haburcak M, Martella G, Tscherter A et al. Impaired dopamine release and synaptic plasticity in the striatum of parkin-/- mice. J Neurochem 2009; 110: 613-621.
41. Palacino JJ, Sagi D, Goldberg MS, Krauss S, Motz C, Wacker M et al. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 2004; 279: 18614-18622.
42. Goldberg MS, Fleming SM, Palacino JJ, Cepeda C, Lam HA, Bhatnagar A et al. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem 2003; 278: 43628-43635.
43. Goldberg MS, Pisani A, Haburcak M, Vortherms TA, Kitada T, Costa C et al. Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonismlinked gene DJ-1. Neuron 2005; 45: 489-496.
44. Farrer M, Chan P, Chen R, Tan L, Lincoln S, Hernandez D et al. Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol 2001; 50: 293-300.
45. Auburger G, Klinkenberg M, Drost J, Marcus K, Morales-Gordo B, Kunz WS et al. Primary skin fibroblasts as a model of Parkinson's disease. Mol Neurobiol 2012; 46: 20-27.
46. Lo Bianco C, Schneider BL, Bauer M, Sajadi A, Brice A, Iwatsubo T et al. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. Proc Natl Acad Sci USA 2004; 101: 17510-17515.
47. Jiang H, Ren Y, Yuen EY, Zhong P, Ghaedi M, Hu Z et al. Parkin controls dopamine utilization in human midbrain dopaminergic neurons derived from induced pluripotent stem cells. Nature Commun 2012; 3: 668.
48. Berger AK, Cortese GP, Amodeo KD, Weihofen A, Letai A, LaVoie MJ. Parkin selectively alters the intrinsic threshold for mitochondrial cytochrome c release. Hum Mol Genet 2009; 18: 4317-4328.
49. Horak P, Crawford AR, Vadysirisack DD, Nash ZM, DeYoung MP, Sgroi D et al. Negative feedback control of HIF-1 through REDD1-regulated ROS suppresses tumorigenesis. Proc Natl Acad Sci USA 2010; 107: 4675-4680.
50. Nguyen QD, Schachar RA, Nduaka CI, Sperling M, Basile AS, Klamerus KJ et al. Phase 1 dose-escalation study of a siRNA targeting the RTP801 gene in age-related macular degeneration patients. Eye 2012; 26: 1099-1105.
51. Malagelada C, Lopez-Toledano MA, Willett RT, Jin ZH, Shelanski ML, Greene LA. RTP801/REDD1 regulates the timing of cortical neurogenesis and neuron migration. J Neurosci 2011; 31: 3186-3196.
52. Greene LA, Tischler AS. Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci USA 1976; 73: 2424-2428.
53. Ryu EJ, Harding HP, Angelastro JM, Vitolo OV, Ron D, Greene LA. Endoplasmic reticulum stress and the unfolded protein response in cellular models of Parkinson's disease. J Neurosci 2002; 22: 10690-10698.